Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Avadel Pharma (AVDL) Tops Q4 EPS by 30c; Reaffirms
March 7, 2017 6:34 AM ESTAvadel Pharma (NASDAQ: AVDL) reported Q4 EPS of $0.00, $0.30 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $43.1 million versus the consensus estimate of $34.95 million.
Total revenues for fourth quarter and full year 2016 were $43.1 million and $150.2 million, compared to $44.6... More